Health Condition 1: I634- Cerebral infarction due to embolism of cerebral arteries
Conditions
Interventions
Intervention1: Apixaban 5mg tablet: Normal dose- Tablet Apixaban 5mg twice daily ( morning and night) after food.
If Apixaban failure occurs, it will be changed to:
Tab Dabigatran 150mg twice dai
Sponsors
Amrita Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Inpatients and outpatients of Department of Stroke medicine and Adult cardiology Patients with and without NOAC failure
Exclusion criteria
Exclusion criteria: History of any mechanical or prosthetic valve replacements Patients on haemodialysis or waiting for any renal replacement surgery Patients who are about to undergo any surgery Patients with congenital coagulation abnormalities Patients who are not willing to participate in the study Patients/caregivers who are unwilling to sign the informed consent Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the prevalence of single nucleotide polymorphisms (SNP) associated with ineffective drug response among patients receiving NOACs for anticoagulation therapy.Timepoint: Six months | — |
Secondary
| Measure | Time frame |
|---|---|
| To establish genetic profiling test for appropriate NOACs for thrombosis prevention with minimal adverse complications (effective NOAC based on individual genomic conditions). Timepoint: Six months;To identify key etiological factors for ineffective anticoagulation in patients taking NOAC. Timepoint: Six months;To assess a cost-effectiveness analysis of pharmacogenomic-guided dosing strategy.Timepoint: Baseline, 3months, 6 months & 1 year. | — |
Countries
India
Contacts
Public ContactDr Chameli Ratan
Amrita Institute of Medical Sciences
Outcome results
None listed